Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation
DARMSTADT, Germany, March 26, 2018 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany (XETRA: MRK.DE, OTC: MKKGY) a leading science and technology company, today announced that their March 22, 2018 presentation is now available for on-demand viewing in the dbVIC Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference.
LINK: https://tinyurl.com/dbvic03postpr
Merck KGaA, Darmstadt, Germany presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the virtual trade booth in the Exhibits section of the event.
Recent Company Highlights
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
Advertisement
DARMSTADT, Germany, March 26, 2018 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany (XETRA: MRK.DE, OTC: MKKGY) a leading science and technology company, today announced that their March 22, 2018 presentation is now available for on-demand viewing in the dbVIC Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference.
Advertisement
LINK: https://tinyurl.com/dbvic03postpr
Merck KGaA, Darmstadt, Germany presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the virtual trade booth in the Exhibits section of the event.
Recent Company Highlights
- Merck Achieves Targets for 2017 – Dividend to Increase
- Merck Announced Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis
- Mavenclad (Cladribine Tablets) Receives First Approval in Latin America, following approval in the EU, Canada, Australia and Israel
- Merck Receives Patents for CRISPR Technology in U.S., Brazil, China, India, Japan, South Korea and Israel
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
View original content:http://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-webcast-presentation-now-available-for-on-demand-viewing-dbvic---deutsche-bank-adr-virtual-investor-conference-300619171.html
SOURCE Merck KGaA
